Clarithromycin
- PDF / 141,318 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 47 Downloads / 151 Views
1
S
Sensorineural hearing loss in an infant: case report A 23-month-old girl developed sensorineural hearing loss during treatment with clarithromycin for cervical atypical mycobacterial infection. The girl had been receiving clarithromycin 85mg twice a day for 7 weeks, increased to 100mg twice a day for a further 8 weeks [route not stated]. An audiogram revealed a sound-field threshold (SFT) at 4000Hz of 50dB HL, and her sound awareness threshold (SAT) was 5dB HL in both ears. Her distortion product otoacoustic emissions (DPOAEs) were absent at 4000Hz. Her hearing loss was suspected to be a result of clarithromycin ototoxicity. A week after the girl’s clarithromycin was withdrawn, her left and right ear thresholds at 4000Hz were ≤20dB HL and 35dB HL, respectively. DPOAEs at 4000Hz continued to be absent in her right ear, but were present in her left ear. Four weeks after clarithromycin withdrawal, her left and right ear thresholds at 4000Hz were both ≤15dB HL, and DPOAEs at 4000Hz were present in both ears. Author comment: "In the current report, reversible audiologic changes occurred in a child taking clarithromycin for AMI [atypical mycobacterial infection]." Whittemore Jr KR, et al. Another cause of ototoxicity: Clarithromycin. International Journal of Pediatric Otorhinolaryngology Extra 6: 419-421, No. 4, Dec 2011. Available from: URL: http://dx.doi.org/10.1016/j.pedex.2011.07.002 803068722 USA
0114-9954/10/1396-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 7 Apr 2012 No. 1396
Data Loading...
